Endometrial Cancer is the most commonly diagnosed gynecologic cancer. An estimated 417,367 people were diagnosed with endometrial cancer in 2020.1
epiHERA™
epiHERA™ is a Minimally Invasive Early Endometrial Cancer Detection Test
Studies have identified that the hypermethylation of specific genes could be used as a biomarker to detect endometrial cancer.2
INEX's Solution
epiHERA™ is a minimally invasive early endometrial cancer detection test that identifies methylated biomarkers which give indications of gene repression from malignancy.
MINIMALLY INVASIVE
Use of simple cervical swab instead of processes like Dilatation & Curettage thus decreasing pain & discomfort.
EASE OF OPERATIONS
Sample collection can be performed in clinics without surgical setup. Fast turnaround time for results from molecular lab instead of a histopathology lab.
EASE OF ADOPTION
Tests can be implemented and performed with simple qPCR lab setup.